Who We Are
TAAV started as a Joint Venture contract manufacturing organization formed by two leading biotechnology organizations within synthetic DNA and AAV manufacturing.
In February 2022, AskBio announced securing 100% ownership of TAAV Biomanufacturing Solutions, SL. TAAV will continue to manufacture AAV dbDNA™ both for third-party customers and AskBio’s internal product development pipeline.
In 2020 TAAV launched its state-of-the-art facility located in San Sebastian, Spain. The facility is comprised of four suites and additional support labs, that are specifically designed for the manufacture of high quality dbDNA™.
We view dbDNA™ as a disruptive technology in the DNA market creating a new industry standard for transfection-based AAV production. Our synthetic process leads to high yield at small scales, shortening manufacturing timelines, facilitating quicker production of AAV and increasing safety by eliminating residual bacterial sequences of plasmid DNA in the AAV product.
Mission
To become the new industry standard DNA for AAV-based gene therapies.
Vision
To be a company with a strong technological base, which creates innovation and is a strategic partner in the development of gene therapies.
Values
We are an ethical company, results-oriented and focused on the value of people above any other consideration. Our primary aim is to contribute to healing those who are beyond the hope of traditional therapeutics.
Leadership/Management Team
Leadership/
Management Team
